FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306255637> ?p ?o ?g. }

• W4306255637 abstract "Abstract Background The effectiveness of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) has not been demonstrated in patients with heart failure with preserved ejection fraction (HFpEF). We recently reported significant interaction between the use of ACE-I and/or ARB (ACE-I/ARB) and frailty on prognosis in patients with HFpEF. Purpose In the present study, we examined the association between ACE-I/ARB and prognosis in patients with HFpEF stratified by the presence or absence of frailty. Methods We examined the association between the use of ACE-I/ARB and prognosis according to the presence (Clinical Frailty Scale (CFS) ≥5) or absence (CFS ≤4) of frailty in patients with HFpEF in a post-hoc analysis of registry data. Primary endpoint was the composite of all-cause mortality and heart failure admission. Secondary endpoints were all-cause mortality and heart failure admission. Results Of 1059 patients, median age was 83 years and 45% were male. Kaplan-Meier analysis showed that the risk of composite endpoint (log-rank P=0.001) and all-cause death (log-rank P=0.005) in patients with ACE-I/ARB was lower in those with CFS ≥5, but similar between patients with and without ACE-I/ARB in patients with CFS ≤4 (composite endpoint: log-rank P=0.830; all-cause death: log-rank P=0.192). In a multivariable Cox proportional hazards model, use of ACE-I/ARB was significantly associated with lower risk of the composite endpoint (hazard ratio = 0.52, 95% CI: 0.33–0.83, P=0.005) and heart failure admission (hazard ratio = 0.45, 95% CI: 0.25–0.83, P=0.010) in patients with CFS ≥5, but not in patients with CFS ≤4 (composite endpoint: hazard ratio = 1.41, 95% CI: 0.99–2.02, P=0.059; heart failure admission: hazard ratio = 1.43, 95% CI: 0.94–2.18, P=0.091). The association between ACE-I or ARB and prognosis did not significantly differ by CFS (CFS ≤4: log-rank P=0.562; CFS ≥5: log-rank P=0.100, for with ACE-I vs. ARB, respectively). Adjusted HRs for CFS 1–4 were higher than 1.0, but were less than 1.0 at CFS 5. Conclusions In patients with HFpEF, use of ACE-I/ARB was associated with better prognosis in patients with frailty as assessed with the CFS, but not in those without frailty. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Roche" @default.
• W4306255637 created "2022-10-15" @default.
• W4306255637 creator A5012777801 @default.
• W4306255637 creator A5020543054 @default.
• W4306255637 creator A5024842874 @default.
• W4306255637 creator A5044203988 @default.
• W4306255637 creator A5050839425 @default.
• W4306255637 creator A5054832481 @default.
• W4306255637 creator A5057699666 @default.
• W4306255637 creator A5058289629 @default.
• W4306255637 creator A5059202386 @default.
• W4306255637 creator A5060227416 @default.
• W4306255637 creator A5064873332 @default.
• W4306255637 creator A5076887260 @default.
• W4306255637 creator A5078596260 @default.
• W4306255637 creator A5083418135 @default.
• W4306255637 creator A5091876475 @default.
• W4306255637 date "2022-10-01" @default.
• W4306255637 modified "2023-10-03" @default.
• W4306255637 title "Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blocker in frail patients with heart failure with preserved ejection fraction" @default.
• W4306255637 doi "https://doi.org/10.1093/eurheartj/ehac544.770" @default.
• W4306255637 hasPublicationYear "2022" @default.
• W4306255637 type Work @default.
• W4306255637 citedByCount "1" @default.
• W4306255637 countsByYear W43062556372022 @default.
• W4306255637 crossrefType "journal-article" @default.
• W4306255637 hasAuthorship W4306255637A5012777801 @default.
• W4306255637 hasAuthorship W4306255637A5020543054 @default.
• W4306255637 hasAuthorship W4306255637A5024842874 @default.
• W4306255637 hasAuthorship W4306255637A5044203988 @default.
• W4306255637 hasAuthorship W4306255637A5050839425 @default.
• W4306255637 hasAuthorship W4306255637A5054832481 @default.
• W4306255637 hasAuthorship W4306255637A5057699666 @default.
• W4306255637 hasAuthorship W4306255637A5058289629 @default.
• W4306255637 hasAuthorship W4306255637A5059202386 @default.
• W4306255637 hasAuthorship W4306255637A5060227416 @default.
• W4306255637 hasAuthorship W4306255637A5064873332 @default.
• W4306255637 hasAuthorship W4306255637A5076887260 @default.
• W4306255637 hasAuthorship W4306255637A5078596260 @default.
• W4306255637 hasAuthorship W4306255637A5083418135 @default.
• W4306255637 hasAuthorship W4306255637A5091876475 @default.
• W4306255637 hasBestOaLocation W43062556371 @default.
• W4306255637 hasConcept C104849204 @default.
• W4306255637 hasConcept C126322002 @default.
• W4306255637 hasConcept C164705383 @default.
• W4306255637 hasConcept C203092338 @default.
• W4306255637 hasConcept C207103383 @default.
• W4306255637 hasConcept C27016395 @default.
• W4306255637 hasConcept C2777099384 @default.
• W4306255637 hasConcept C2778198053 @default.
• W4306255637 hasConcept C2779611605 @default.
• W4306255637 hasConcept C2779668873 @default.
• W4306255637 hasConcept C2908929049 @default.
• W4306255637 hasConcept C44249647 @default.
• W4306255637 hasConcept C50382708 @default.
• W4306255637 hasConcept C535046627 @default.
• W4306255637 hasConcept C71924100 @default.
• W4306255637 hasConcept C78085059 @default.
• W4306255637 hasConcept C84393581 @default.
• W4306255637 hasConceptScore W4306255637C104849204 @default.
• W4306255637 hasConceptScore W4306255637C126322002 @default.
• W4306255637 hasConceptScore W4306255637C164705383 @default.
• W4306255637 hasConceptScore W4306255637C203092338 @default.
• W4306255637 hasConceptScore W4306255637C207103383 @default.
• W4306255637 hasConceptScore W4306255637C27016395 @default.
• W4306255637 hasConceptScore W4306255637C2777099384 @default.
• W4306255637 hasConceptScore W4306255637C2778198053 @default.
• W4306255637 hasConceptScore W4306255637C2779611605 @default.
• W4306255637 hasConceptScore W4306255637C2779668873 @default.
• W4306255637 hasConceptScore W4306255637C2908929049 @default.
• W4306255637 hasConceptScore W4306255637C44249647 @default.
• W4306255637 hasConceptScore W4306255637C50382708 @default.
• W4306255637 hasConceptScore W4306255637C535046627 @default.
• W4306255637 hasConceptScore W4306255637C71924100 @default.
• W4306255637 hasConceptScore W4306255637C78085059 @default.
• W4306255637 hasConceptScore W4306255637C84393581 @default.
• W4306255637 hasIssue "Supplement_2" @default.
• W4306255637 hasLocation W43062556371 @default.
• W4306255637 hasOpenAccess W4306255637 @default.
• W4306255637 hasPrimaryLocation W43062556371 @default.
• W4306255637 hasRelatedWork W2011139229 @default.
• W4306255637 hasRelatedWork W2023799771 @default.
• W4306255637 hasRelatedWork W2027691053 @default.
• W4306255637 hasRelatedWork W2052242574 @default.
• W4306255637 hasRelatedWork W2622922034 @default.
• W4306255637 hasRelatedWork W2779222010 @default.
• W4306255637 hasRelatedWork W2950884396 @default.
• W4306255637 hasRelatedWork W2975860702 @default.
• W4306255637 hasRelatedWork W4220670965 @default.
• W4306255637 hasRelatedWork W4306255637 @default.
• W4306255637 hasVolume "43" @default.
• W4306255637 isParatext "false" @default.
• W4306255637 isRetracted "false" @default.
• W4306255637 workType "article" @default.